How Can We Help You with Your Projects?

Contact us to discuss the specifics of your project. Our team of experienced scientists is ready to assist you with tailored solutions to meet your unique needs. Whether you need help with assay development, FDA IND, stability study, lot release approval, or other scientific endeavors, we are here to support you.Contact us to learn more about our cell based assay services

How Long Does It Take to Get Started?

We will initiate your project as soon as the proposal is approved and signed by you. Our streamlined process ensures a quick start, minimizing delays and maximizing efficiency. Fill out the form below to email us or click our live chat option to speak with a MarinBio Scientist and get your project underway.

Can You Help with Assay Development and Validation for FDA IND, Lot Release and Stability Study Approval?

Yes, we have over 30 years of expertise in developing and validating cell based assays for FDA IND, lot release or stability study approval. Our team can also liaise directly with the FDA on your behalf, ensuring a smooth and compliant process. Please contact us to learn more about how we can assist you with your assay development and FDA approval needs.

Do You Need a Custom or Tailored Assay?

MarinBio scientists are experienced and creative in designing, developing, validating assays. Some of the assays we perform are listed below, but there are many more that we created, developed and validated. Give us call so that we may help you.

Cell Based Assays for Antigen Specific Tolerance

Antigen-specific tolerance is a fundamental aspect of immune regulation, critical in the context of both autoimmune disease and cancer. In vitro assays using human immune cells provide a mechanistic platform to measure tolerance and evaluate candidate tolerogenic drugs. These assays differ in the immune cell types used, antigen sources, readout formats, and sensitivity to drug-induced tolerance.

Antigen Specificity

In an immune response, “antigen-specific” refers to immune activity that is directed solely against a particular antigen, a defined peptide, protein, or molecular structure, rather than acting broadly or nonspecifically. Antigen-specific T cells recognize a single peptide-MHC complex through their unique T-cell receptor. Similarly, antigen-specific B cells and antibodies bind only to a particular epitope on an antigen, for example an antibody that binds tetanus toxoid (inactivated toxin) but not diphtheria toxoid.

This specificity arises from clonal selection, where only lymphocytes whose receptors match the antigen become activated and expand, and from the precise molecular recognition mediated by TCRs and BCRs/antibodies. As a result, effector functions, such as cytokine secretion, cytotoxicity, or antibody production, remain tightly focused on the cells or molecules displaying that antigen. Antigen specificity is essential for selective immunity, effective vaccination, and the assessment of immune tolerance, where reduced antigen-specific activation can indicate the presence of a tolerogenic state.

Definitions

–Immunological tolerance: The immune system’s ability to avoid attacking the body’s own tissues while remaining responsive to foreign antigens.

–Antigens: Molecules, often proteins or polysaccharides, that are recognized by the immune system and can trigger an immune response.

–Self-antigens: Normal molecules produced by the body that can be recognized by the immune system but normally do not elicit an immune response.

–Autoreactive: Referring to immune cells that recognize and can potentially attack the body’s own tissues.

–Self-reactivity: The capacity of an immune cell or antibody to bind to the body’s own molecules.

—Negative selection: The process in primary lymphoid organs where developing T or B cells that strongly recognize self-antigens, are eliminated to prevent autoimmunity.

—Anergy: A state in which immune cells are alive but functionally unresponsive to their specific antigen, preventing an immune attack.

Immunological Tolerance (Immune Tolerance)

Unwanted dysregulation of tolerance can induce the attack over the body’s own tissues leading to autoimmune disorders, graft rejection, and chronic inflammatory conditions. In contrast, excessive tolerance can permit tumor progression. In vitro human immune cell assays allow researchers to quantify tolerance at a mechanistic level, providing critical tools to screen drugs that either restore or modulate immune responses in a controlled, antigen-specific manner.

Immunological tolerance can be broadly categorized into central tolerance and peripheral tolerance. While central tolerance occurs in primary lymphoid organs like the thymus and the bone marrow where self-reactive lymphocytes are eliminated during their development, peripheral tolerance regulates mature lymphocytes in secondary lymphoid tissues and peripheral organs. Some mechanisms of peripheral tolerance include:

T cell anergy: T cells fail to respond to antigen due to inadequate co-stimulation, often mediated by inhibitory receptors such as CTLA-4 or PD-1.
Regulatory T cell (Treg) suppression: CD4⁺CD25⁺FOXP3⁺ Tregs inhibit effector T cell proliferation and cytokine production through cell-contact-dependent mechanisms and secretion of suppressive cytokines like IL-10 and TGF-β.
Tolerogenic antigen presentation: Dendritic cells (DCs) or other antigen-presenting cells can induce hypo-responsiveness or Treg differentiation by presenting antigens in a non-inflammatory context.
B cell tolerance: Includes deletion of autoreactive B cells, anergy, and regulation by T cell help, ensuring controlled antibody responses.

Clinically, enhancing tolerance is beneficial in autoimmune diseases and transplantation, where immune-mediated tissue damage must be controlled. Conversely, inhibiting tolerance can improve anti-tumor immunity in cancer therapy by reactivating T cells that have become exhausted or anergic. Understanding tolerance mechanisms is therefore essential for rational drug development.

Evaluating Antigen-Specific Tolerance in Vitro

Memory T Cell Recall Peptides

Memory T cell recall peptides are widely used in human in vitro immunological assays to evaluate antigen-specific T cell responses. These peptides represent epitopes derived from pathogens or vaccines to which the donor has previously been exposed, generating a pool of memory T cells. Upon in vitro stimulation with these peptides, antigen-specific CD4⁺ or CD8⁺ T cells recognize the peptide–MHC complexes presented by autologous antigen-presenting cells (APCs). This recognition triggers rapid activation, proliferation, and effector function, including cytokine secretion, which can be measured to assess the magnitude and quality of the memory T cell response. The use of well-characterized recall peptides allows for reproducible and controlled evaluation of antigen-specific immunity, making them valuable tools for studying immunological tolerance, vaccine responses, or functional T cell capacity in human peripheral blood mononuclear cells (PBMCs).

Table 1. Well-characterized memory T cell recall peptides commonly used in human in vitro antigen-specific immunological assays

Peptide / Antigen	Source	Notes / Use in Human In Vitro Assays
CEF Pool Peptides (CMV, EBV, Flu)	CMV pp65, EBV BMLF1, Influenza M1	Standard positive control for CD8⁺ T cell recall responses; widely used in human PBMC assays
TT830–843	Tetanus toxoid	CD4⁺ T cell epitope; robust recall responses in vaccinated individuals
M1 58–66	Influenza A virus	CD8⁺ T cell epitope; standard for memory T cell assays
CMV pp65 495–503 (NLVPMVATV)	Cytomegalovirus	CD8⁺ T cell epitope; widely used for memory T cell studies
EBV BMLF1 280–288 (GLCTLVAML)	Epstein–Barr virus	CD8⁺ T cell epitope; strong recall in EBV-exposed adults
TT 1270–1283	Tetanus toxoid	CD4⁺ T cell epitope; alternative for recall in tetanus-vaccinated donors
Flu M58–66	Influenza A virus	CD8⁺ T cell epitope; standard influenza recall peptide
PPD-derived peptides	Mycobacterium tuberculosis protein derivative	Stimulates memory CD4⁺ T cells in BCG-vaccinated donors; widely used in human in vitro studies
Candin (Candida albicans) peptides	Candida albicans	Memory CD4⁺ T cell recall peptides; used to assess tolerance or immunoreactivity in vitro
Streptolysin O peptide fragments	Streptococcus pyogenes	Memory CD4⁺ T cell epitopes in adults with prior exposure; used in human PBMC assays

Assays for Antigen-Specific Tolerance

1-Antigen-Specific T Cell Proliferation and Cytokine Suppression

The mechanistic rationale for this assay is that T cell proliferation is a hallmark of antigen recognition, and suppression of proliferation indicates the induction of antigen-specific tolerance. In addition, antigen-specific tolerance can manifest as reduced cytokine production and upregulation of inhibitory receptors in T cells. This assay primarily interrogates pre-existing antigen-experienced memory T cells, which rapidly proliferate and produce effector cytokines upon re-exposure to cognate antigen (recall response). In this assay, peripheral blood mononuclear cells (PBMCs) or isolated CD4⁺ and CD8⁺ T cells are exposed to peptide, protein, or whole pathogen-derived antigens. Antigen-specific recall responses are driven predominantly by central and effector memory T cell subsets, enabling sensitive detection of changes in proliferation and cytokine production. Tolerogenic drugs are expected to attenuate memory T cell activation by inducing anergy, functional exhaustion, or regulatory mechanisms, resulting in reduced antigen-specific proliferation and cytokine secretion. Readouts include flow cytometry using proliferation dyes to track memory T cell division and cytokine quantification via ELISA or bead-based assays.

Cellular and molecular events
Upon antigen exposure, antigen presenting cells (APCs) in PBMCs present peptides on MHC-I or MHC-II, leading to TCR engagement and signaling that drives cytokine production and T cell proliferation. Tolerogenic drugs suppress these activation pathways by reducing co-stimulation and IL-2 signaling while enhancing inhibitory receptors such as PD-1 or CTLA-4. As a result, antigen-specific T cells show reduced proliferation, diminished cytokine production, and may enter an anergic or hypo-responsive state.

2-Antigen-Induced Regulatory T Cell (Treg) Functional Assay
This assay is designed to measure the ability of Tregs to mediate antigen-specific suppression of effector T cells. The underlying rationale is that enhancing Treg function is a primary mechanism of peripheral tolerance. Tregs are co-cultured with responder T cells in the presence of peptide or protein antigens presented by autologous APCs. Suppression is quantified via flow cytometry and cytokine measurements. This assay is highly sensitive to drugs that enhance Treg function, making it ideal for evaluating therapeutic strategies aimed at restoring immune homeostasis in autoimmune diseases.

Cellular and molecular events
During co-culture, antigen-loaded APCs activate effector T cells while also engaging Treg-mediated suppression. Tregs inhibit responses through CTLA-4–dependent modulation of APC co-stimulation, IL-2 consumption, and suppressive cytokines such as IL-10 and TGF-β. Additional inhibitory pathways may contribute depending on the Treg subset. Tolerogenic drugs that stabilize Tregs enhance this suppression, resulting in reduced effector T cell proliferation and cytokine production.

3-Tolerogenic Dendritic Cell (DC) Induction Assay
This assay assesses whether DCs can induce T cell hypo-responsiveness or Treg differentiation, reflecting the capacity of DCs to promote peripheral tolerance. Monocyte-derived DCs are co-cultured with memory T cells and exposed to protein/peptide antigens or antigen-loaded cells. Readouts include flow cytometry, cytokine profiling, and Treg frequency analysis. The assay is suitable for testing drugs that promote a tolerogenic DC phenotype and downstream T cell tolerance.

Cellular and molecular events
During culture, monocyte-derived DCs process antigens and present them on MHC molecules. Tolerogenic drugs suppress DC maturation and co-stimulatory molecule expression while promoting anti-inflammatory mediators such as IL-10, TGF-β, and IDO. These tolerogenic DCs limit T cell activation, favor Treg induction or anergy, and reduce memory T cell signaling and proliferation.

4-Mixed Lymphocyte Reaction (MLR) / Allogeneic Antigen-Specific Suppression
Although not strictly antigen specific, the MLR evaluates tolerance in the context of allogeneic responses. The mechanistic rationale is that a tolerogenic drug should reduce T cell proliferation and cytokine production in response to foreign or allogeneic antigens. Allogeneic PBMCs or T cells are co-cultured with antigen-presenting cells, and proliferation and cytokine levels are quantified using flow cytometry, or ELISA. The assay is effective for detecting broad immunosuppressive effects of candidate drugs.

Cellular and molecular events
In an allogeneic MLR, donor and recipient APCs express mismatched MHC molecules that strongly activate responding T cells. Direct allorecognition leads to rapid TCR engagement with foreign MHC–peptide complexes, robust calcium signaling, and high IL-2 and IFN-γ production driving proliferation. Tolerogenic drugs dampen APC activation, inhibit IL-2 autocrine loops, or enhance inhibitory receptor pathways. Reduced co-stimulatory engagement and increased PD-1/PD-L1 interactions shift cells into hyporesponsive states. Over time, T cells may enter partial anergy or develop regulatory phenotypes, lowering proliferation and inflammatory cytokine secretion.

5-Antigen-Specific B Cell/T Cell Interaction Assay
This assay examines tolerance in humoral immunity, focusing on T-dependent B cell responses. The rationale is that tolerogenic interventions can reduce B cell activation, class-switching, or antibody production by modulating T-B cell collaboration. B cells and antigen-specific T helper cells are co-cultured with protein antigens recognized by the BCR. Readouts include ELISPOT for IgG/IgM and flow cytometry.

Cellular and molecular events
Protein antigens are taken up by B cells via the B cell receptor (BCR) and presented on MHC-II to helper T cells, which provide CD40- and cytokine-dependent signals that drive B cell proliferation, class switching, and antibody production. Tolerogenic drugs interfere with these activation signals or enhance regulatory pathways, leading to reduced B cell differentiation and lower antibody secretion.

6-T cell receptor (TCR) Transgenic Antigen-Specific Reporter Assay
This assay uses engineered human T cells expressing a genetically defined antigen specific TCR to measure antigen-specific tolerance. The mechanistic rationale is that tolerance reduces TCR-mediated signaling, which can be quantified via reporter gene activation. Human TCR-transgenic T cells are exposed to APCs presenting the cognate peptide antigen, and reporter activity is measured via luciferase or fluorescence. This assay is highly sensitive, capable of detecting subtle changes in T cell responsiveness, making it ideal for precise drug screening.

Cellular and molecular events
Upon antigen recognition, the engineered TCR initiates proximal signaling via Lck, ZAP-70, and downstream cascades (MAPK, NFAT, NF-κB). Reporter genes, often driven by NFAT, IL-2 promoter fragments, or AP-1 response elements, are activated proportionally to signal strength. Tolerogenic drugs reduce these pathways by limiting co-stimulation, enhancing inhibitory phosphatases or altering metabolic fitness. As a result, reporter activation (luciferase or fluorescent output) drops, reflecting decreased TCR signaling amplitude even when antigen is present. This provides a precise readout of molecular-level tolerance induction.

Screening Drugs for Tolerance Induction

Collectively, these assays allow mechanistic evaluation of candidate tolerogenic drugs. Depending on their target, drugs may enhance Treg activity, induce T cell anergy or exhaustion, or promote tolerogenic DC differentiation. Sensitivity and specificity vary by assay, so multiple complementary platforms are often employed to confirm efficacy and elucidate the mechanism of action. High-sensitivity assays, such as TCR-transgenic reporter systems, are particularly useful in early discovery for identifying agents with subtle but meaningful effects.

Table 2 presents a panel of in vitro human immune cell assays designed to measure antigen-specific tolerance and evaluate the effects of therapeutic candidates on immune regulation. These assays are particularly useful for testing drugs aimed at autoimmune disease therapy, as they allow mechanistic assessment of how different interventions modulate T cell and B cell responses, promote regulatory cell function, or induce functional hyporesponsiveness. Each assay captures distinct aspects of the immune response, ranging from T cell proliferation and cytokine production to dendritic cell tolerogenicity and B/T cell interactions, making them relevant for assessing specific immune mechanisms and informing therapeutic strategies for targeted disease indications.

Table 2. Drug Candidates That Regulate Immune Tolerance

Assay	Drug Candidate	Drug Modality	Mechanism of Action Relevant to Tolerance	Therapeutic Indication
1. Antigen Specific T Cell Proliferation and Cytokine Suppression (Recall Response)	Abatacept (CTLA4-Ig)	Recombinant fusion protein	Binds CD80/86 on APCs, blocking CD28 co-stimulation, decreases cytokine production and proliferation, induces T cell anergy and reduces recall responses.	Arthritis, GVHD
2. Antigen Induced Regulatory T Cell (Treg) Functional Assay	Low-dose IL-2 (e.g., NKTR-358/Lirilumab-IL-2 conjugates)	Cytokine or cytokine agonist	Selectively expands FOXP3⁺ Tregs via high-affinity IL-2 receptor engagement (CD25), enhancing suppressive function and restoring immune tolerance in autoimmunity.	Variety of autoimmune diseases, allogeneic transplantation
3. Tolerogenic Dendritic Cell (DC) Induction Assay	Vidofludimus calcium (IMU-838)	Small-molecule DHODH inhibitor	Suppresses DC maturation and pro-inflammatory cytokine production (IL-12, TNF), promotes tolerogenic DC phenotype, indirectly enhancing T cell tolerance.	Autoimmune disease therapy (e.g., type 1 diabetes, rheumatoid arthritis)
4. Mixed Lymphocyte Reaction (MLR) – Tolerance	Alefacept	Recombinant fusion protein (LFA-3/IgG1)	Binds CD2 on T cells, dampening allo-reactive T cell activity and promoting immune tolerance.	Transplant tolerance, graft-versus-host disease (GVHD)
5. Antigen Specific B/T Cell Interaction Assay	Rilonacept / Anakinra (IL-1 blockade)	Biologic cytokine trap or receptor antagonist	Inhibits IL-1–driven T cell help and B cell activation, reducing class-switching and antibody production, dampens T-dependent humoral immune responses.	Autoimmune disease therapy
6. TCR-Transgenic Antigen Specific Reporter Assay	mTOR inhibitors (Rapamycin/ Sirolimus)	Small-molecule mTORC1 inhibitor	Suppresses TCR signaling strength, reduces NFAT/AP-1 transcriptional activity, promotes Treg-biased differentiation reduces reporter activity and models antigen-specific tolerance induction.	Precision immunotherapy, antigen-specific tolerance research

Conclusion

Human cell-based assays for measuring antigen-specific tolerance provide a critical platform for advancing our understanding of immune regulation and for evaluating the efficacy of novel therapeutics. These in vitro systems enable precise assessment of how immune cells respond to defined antigens, offering mechanistic insight into the cellular and molecular processes that underpin tolerance. The ability to measure antigen-specific responses is particularly important in the context of autoimmune diseases, where dysregulated immune recognition drives pathology. Developing drugs that can selectively restore or induce tolerance has the potential to transform treatment, shifting from broad immunosuppression toward targeted immunomodulation that preserves protective immunity. In this landscape, antigen-specific tolerance assays are indispensable tools for preclinical drug development, enabling the screening and optimization of therapeutic candidates in a controlled human-relevant setting. Ultimately, these assays not only accelerate the discovery of safer and more effective treatments for autoimmune diseases but also provide a mechanistic framework to guide precision immunotherapy strategies.

Disclaimer: This blog post is intended solely for educational and scientific informational purposes. Any mention of therapeutic drug names, including FDA-approved medications, is for the purpose of accurate reporting and discussion of biomedical research and does not constitute medical advice, endorsement, or promotion. Readers should not interpret the content as a recommendation for any specific treatment. Always consult a qualified healthcare professional for medical advice or treatment decisions.

About Marin Biologic Laboratories

Our Recent Publication/Meeting Presentation on Gene Therapy

1. Development of VNX-101, an Adeno-Associated Virus with Less Immunogenicity and Efficient Long-Term Expression of a CD19 T-Cell Engager. Molecular Therapy Methods & Clinical Development, published online July 24, 2025.

3. Cell-Based Potency Assay for Anti-CD3-Anti-CD19 Diabody. Journal of Immunological Methods. 2025. 545-114004.

3. Development of a Pharmacokinetic (PK) Mouse Serum GLP ELISA for an Anti–CD19–AntiCD3 Diabody
bioRxiv 2025.03.19.644217; doi: https://doi.org/10.1101/2025.03.19.644217.

4. American Society of Hematology (ASH) Annual Meeting 2024.
Abstract link: Using Gene Therapy to Solve Challenges with CAR-T Cell Immunotherapy: Lead Selection and Preclinical Development of an Adeno-Associated Virus with Reduced Immunogenicity Exhibiting Efficient and Long-Term Expression of an Anti-CD19 T-Cell Engager.

Comprehensive Assay Solutions for In Vitro and Cell Based Potency Assays and Pharmacokinetics Studies- Our Expertise

With 30 years of expertise in cell culture, cell-based assays, and preclinical/clinical PK/PD analysis, we specialize in offering assay services essential for a wide variety of therapeutic drug development programs, preclinical studies, IND/BLA applications, and commercialization. Our comprehensive services include both preclinical non-GLP and GLP assays, as well as non-GMP and GMP assays, providing critical support throughout the entire development pipeline.

Watch the following video and explore our latest presentation on the development and validation of potency and pharmacokinetic (PK) assays for AAV vectors, highlighting innovative methodologies and industry-leading expertise.